{"id":2964,"date":"2026-09-08T06:50:00","date_gmt":"2026-09-08T10:50:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2964"},"modified":"2026-09-08T20:40:27","modified_gmt":"2026-09-09T00:40:27","slug":"deucrictibant-xr-reduces-hereditary-angioedema-attacks","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2964","title":{"rendered":"Deucrictibant XR Reduces Hereditary Angioedema Attacks"},"content":{"rendered":"

Evidence<\/strong> Source gap catch-up · Published<\/strong> September 8, 2026 · Discovery<\/strong> September 8, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Positive<\/p>\n

\"Deucrictibant<\/p>\n

Summary<\/h4>\n

Pharvaris reported that once-daily oral deucrictibant XR reduced mean monthly hereditary-angioedema attack rates by 83% versus placebo in the pivotal Phase III CHAPTER-3 study. The 85-participant trial met its primary endpoint and all multiplicity-controlled secondary efficacy endpoints, with early and sustained protection over 24 weeks. The result substantially de-risks prophylactic efficacy for the oral bradykinin B2-receptor antagonist. Absolute attack rates, confidence intervals, subgroup detail and complete laboratory and safety data remain undisclosed, so cross-trial equivalence to injectable prophylaxis cannot be claimed.<\/p>\n

What Happened<\/h4>\n

CHAPTER-3 randomized adolescents and adults from 21 countries two to one to deucrictibant XR 40 mg once daily (n=55) or placebo (n=30) for 24 weeks. It enrolled HAE types 1 and 2 and HAE with normal C1 inhibitor. Across all types, the mean monthly attack rate was 83% lower with deucrictibant than placebo (p<0.0001). Among the 80 participants with type 1 or type 2 disease, the reduction was 87%. The company said results were consistent across subgroups, but the normal-C1-inhibitor subgroup contained only five participants in aggregate.<\/p>\n

Protection appeared within the first week and was sustained through Week 24. The company also reported higher attack-free proportions, improved disease control and health-related quality of life, with all sequentially tested secondary endpoints significant. Most treatment-emergent adverse events were mild or moderate; no treatment-related serious adverse event was reported, and one participant in each arm discontinued because of an adverse event. CHAPTER-4 long-term follow-up is ongoing, and a U.S. prophylaxis application is planned for the first half of 2027.<\/p>\n

Deep Analysis<\/h4>\n

Oral B2 blockade can support high-level prophylaxis:<\/strong> The randomized effect size, rapid onset, persistence and multiplicity-controlled secondary results collectively support mechanism validation in prevention, not only on-demand treatment. A once-daily tablet could reduce injection burden and allow one molecular franchise across acute and prophylactic care. Absolute disease control, adherence, rescue-medication use and patient-level durability are not yet visible; an 83% relative reduction can represent different residual burdens depending on placebo rate.<\/p>\n

The topline package may look stronger than the full dataset:<\/strong> The trial is small, lasts six months and has a two-to-one allocation, leaving only 30 placebo recipients. Rare safety events, laboratory abnormalities and performance in the heterogeneous normal-C1-inhibitor population cannot be characterized well. The company’s “injectable-like efficacy” language is a cross-trial claim, not evidence from a randomized injectable comparator. Against a pure reporting-bias explanation, the primary endpoint and every secondary within the prespecified testing hierarchy reportedly met significance.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts include 85 randomized participants, 40 mg once daily, 24-week treatment, 83% overall relative attack-rate reduction, 87% reduction in type 1 or 2 disease and no treatment-related serious event reported. Company claims include cross-formulation franchise potential and injectable-like efficacy. Missing facts include absolute attack rates, confidence intervals, attack-free percentages, full endpoint estimates, baseline severity, adherence, subgroup interactions, liver chemistry and exposure-response.<\/p>\n

Company and Product Background<\/h4>\n

Pharvaris is developing deucrictibant in extended-release tablets for prophylaxis and immediate-release capsules for on-demand treatment of bradykinin-mediated angioedema. The immediate-release U.S. application is already under review; the prophylaxis filing is planned for the first half of 2027. This dual-formulation strategy is operationally coherent, but approval, labeling and commercial uptake must be assessed independently for each formulation.<\/p>\n

Hereditary angioedema is a rare disorder of episodic, potentially life-threatening swelling driven by excess bradykinin. Types 1 and 2 involve quantitative or functional C1-inhibitor deficiency; disease with normal C1 inhibitor is genetically and clinically heterogeneous. Bradykinin activates the B2 receptor on vascular endothelium, increasing permeability. Deucrictibant is an orally bioavailable small-molecule B2 antagonist designed to interrupt that final common pathway. Extended release aims to maintain preventive exposure across the dosing interval.<\/p>\n

InSilens Take<\/h4>\n

CHAPTER-3 is a pivotal positive signal: oral B2-receptor blockade produced a large placebo-controlled reduction in attack frequency and cleared the prespecified efficacy hierarchy. The result supports a favorable efficacy interpretation for deucrictibant XR, while the small and short topline dataset limits safety, subgroup and comparative conclusions. Regulatory review will turn on the complete statistical package, laboratory safety, formulation performance and whether the total evidence supports prevention across the proposed population.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — CHAPTER-3 is the pivotal prophylaxis study for a potentially differentiated oral therapy in a serious rare disease<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — the primary endpoint and all multiplicity-controlled secondary efficacy endpoints favored deucrictibant XR<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — core design, sample size, relative effects and initial safety disclosed in a primary release and registry<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-high — pivotal efficacy appears persuasive, while full safety, subgroup and absolute-rate data remain unavailable<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Pharvaris reported that once-daily oral deucrictibant XR reduced mean monthly hereditary-angioedema attack rates by 83% versus placebo in the pivotal Phase III CHAPTER-3 study. The 85-participant trial met its primary endpoint and all multiplicity-controlled…<\/p>\n","protected":false},"author":1,"featured_media":2972,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[621,620,116,619],"class_list":["post-2964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-bradykinin-b2-receptor","tag-deucrictibant","tag-hereditary-angioedema","tag-pharvaris"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2964"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2964\/revisions"}],"predecessor-version":[{"id":2995,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2964\/revisions\/2995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2972"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}